<DOC>
	<DOCNO>NCT00446849</DOCNO>
	<brief_summary>To evaluate percentage subject clinical recurrence UC 6 month use MMX mesalamine daily .</brief_summary>
	<brief_title>Strategies Maintenance Patients Receiving Long-term Therapy ( S.I.M.P.L.E . ) With MMX ( Multi-Matrix System ) Mesalamine Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Inclusion Criteria Acute Phase : 1 . Male female subject age least 18 year active mild moderate UC may enter Acute Phase study . 2 . Must previous diagnosis UC confirm histology endoscopy radiology . 3 . Males nonpregnant , nonlactating FOCP negative serum pregnancy test prior enter study use adequate form contraception duration study . 4 . General medical assessment must satisfactory must clinically significant relevant abnormality . 5 . Subject must &gt; 2 acute episode UC ( documented episode increase bowel frequency rectal blood loss UC therapy intensify ) medical history . 6 . Subjects relapse maintenance therapy 2 week dose mesalamine : . &lt; 2.0g/day , allow Acute Phase 2.4g/day QD , b. 2.0g/day 3.0g/day allow Acute Phase 4.8g/day QD . Inclusion Criteria Maintenance Phase : 1 . Subjects determine quiescent study entry prior oral mesalamine therapy eligible enter directly Maintenance Phase . 2 . UC must consider quiescent , score zero rectal bleed bowel movement . Exclusion Criteria Acute Phase : 1 . Subjects relapse &gt; 6 week . 2 . Female subject pregnant lactating , include female positive pregnancy test screening . 3 . Subjects must use another investigational agent within last 30 day prior enrollment . 4 . Subjects unsuccessfully treat current relapse steroid mesalamine dose &gt; 2.0 g/day . 5 . Subjects relapse maintenance therapy dose mesalamine &gt; 2.0g/day . If subject recent dose reduction 2.0g/day less equal 2.0g/day relapse within 2 week dose reduction , subject eligible . 6 . Subjects use systemic rectal steroid within last 4 week prior Baseline , immunosuppressant within last 6 week , antibiotic use within last 7 day chronic use antiinflammatory drug within 7 day prior Baseline . 7 . Subjects hypersensitivity salicylates/aspirin exclude . 8 . Subjects moderate severe hepatic impairment . 9 . Subjects Crohn 's Disease , proctitis ( extent inflammation less equal 15cm ) , short bowel syndrome , bleed disorder , active peptic ulcer disease . 10 . Subjects asthma exclude know mesalaminesensitive . 11 . Subjects positive stool culture enteric pathogen ( include Salmonella , Shigella , Yersinia , Aeromonas , Plesiomonas Campylobacter ) exclude , C. difficile toxin present ova parasite detect microscopy . 12 . Subjects history previous colonic surgery . 13 . Subjects moderate severe renal impairment contraindicate treatment mesalamine compound exclude study . 14 . Subjects current recurrent disease could affect colon , action , absorption disposition study drug , clinical laboratory assessment . 15 . Subjects current relevant previous history serious , severe unstable ( acute progressive ) physical psychiatric illness , medical disorder may require treatment make patient unlikely fully complete study , condition present undue risk study drug procedure . 16 . Subjects history alcohol substance abuse within previous year . 17 . Subjects withdraw mesalamine trial due possibly probably relate severe AE SAE eligible enter study . Exclusion Criteria Maintenance Phase ( addition inclusion Acute Phase ) : 1 . Subjects withdraw Acute Phase study visit A3 . 2 . Subjects severe UC accord PGA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>compliance</keyword>
	<keyword>mesalamine</keyword>
	<keyword>clinical study</keyword>
	<keyword>clinical trial</keyword>
	<keyword>clinical research</keyword>
	<keyword>maintenance</keyword>
	<keyword>long term</keyword>
	<keyword>uc study</keyword>
	<keyword>uc trial</keyword>
	<keyword>uc research</keyword>
	<keyword>open label</keyword>
	<keyword>day</keyword>
	<keyword />
	<keyword>daily</keyword>
	<keyword>daily dose</keyword>
	<keyword>simple</keyword>
	<keyword>oral</keyword>
</DOC>